Celanese Corp Del Stock Price, News & Analysis

Celanese Corporation (NYSE: CE) has announced a quarterly cash dividend of $0.70 per share on its common stock. This dividend will be payable on May 15, 2023, to stockholders of record as of May 1, 2023. Celanese is a global leader in specialty materials and chemical production, with a workforce of approximately 13,000 employees worldwide and reported net sales of $9.7 billion in 2022. The company utilizes its extensive chemistry and technology expertise to create value across various industries and consumer applications.

Celanese Corporation (NYSE: CE) has announced a conference call to discuss its first quarter 2023 results on May 10, 2023, at 10:00 a.m. Eastern time. The earnings press release will be distributed after market close on May 9, 2023. Investors can access the call via webcast or by phone, with a dial-in number of 1-877-407-0989 for domestic participants. A replay will be available from May 10 to May 24, 2023. Celanese reported net sales of $9.7 billion in 2022 and continues to strengthen its position as a leader in the chemical industry.

Celanese (NYSE: CE) has announced a partnership with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for the iDose® TR intraocular implant. This device aims to lower intraocular pressure in patients with glaucoma by providing continuous, long-duration therapy, addressing issues of patient non-adherence to topical medications. Glaukos submitted a New Drug Application for iDose TR in February 2023, pending FDA approval. The collaboration is aimed at enhancing patient treatment options in ophthalmology, leveraging the proven performance of Celanese's VitalDose technology, which has a solid history of controlled-release applications.

Celanese Corporation (NYSE: CE) has announced a collaboration with Alessa Therapeutics to develop a new oncology drug using Alessa's sustained localized drug delivery technology. The partnership aims to enhance treatment for oncology patients by reducing systemic side effects.

According to Alessa's Vice President, the collaboration has facilitated the rapid development of their drug candidate, with plans to advance to human studies later this year. Celanese emphasized its commitment to improving therapeutic outcomes through innovative drug delivery solutions.

Celanese Corporation (NYSE: CE), a leader in specialty materials, announced price hikes for Hytrel® TPC resins, set to take effect on March 15, 2023. The increases include 0.45 EUR/kg in the EMEA region and 0.5 USD/kg in both Asia Pacific and the Americas. Individual grades may experience greater hikes as per contract terms. Celanese, headquartered in Dallas, reported $9.7 billion in net sales for 2022 and employs around 13,000 people globally.

Celanese Corporation (NYSE: CE) reported record GAAP diluted EPS of $17.41 and adjusted EPS of $15.88 for 2022, achieving net sales of $9.7 billion, up 13% from 2021. Despite significant raw material and energy cost inflation of over $1.2 billion, the company offset these pressures through pricing increases. The acquisition of DuPont's Mobility & Materials business significantly contributed to Celanese's performance. In Q4 2022, GAAP diluted EPS was $7.03, with adjusted EPS of $1.44, reflecting challenges from destocking and demand fluctuations, particularly in Asia. The company anticipates improved earnings in Q1 2023, projecting adjusted EPS between $1.50 to $1.75.

Celanese Corporation (NYSE: CE) announced a strategic partnership expansion with Mitsui & Co., Ltd., including a new Food Ingredients joint venture (JV) and an extension of the Fairway Methanol LLC JV. Celanese will contribute its Food Ingredients business to the JV, retaining a 30% stake, while Mitsui will own 70%. The Food Ingredients segment generated $170 million in 2022 net sales and $45-$50 million in EBITDA. The Fairway Methanol JV will now operate through 2045 and is set for an expansion to 1.62 million metric tons, utilizing recycled CO₂ in production. The expected closure for these transactions is Q3 2023, with proceeds aimed at debt reduction.

Celanese Corporation (NYSE: CE) announced the successful completion of an ultra-low capital project to boost ethylene vinyl acetate (EVA) capacity at its Edmonton, Alberta facility. This expansion will provide a 35% increase in EVA capacity starting Q1 2023, contributing approximately $10 million per year in additional operating EBITDA. The demand for EVA, particularly in solar applications, is projected to grow at a double-digit compounded annual rate through 2028. This strategic move strengthens Celanese's position in the acetyls market, enhancing its capability to meet rising demand across various high-value applications.

Celanese Corporation (NYSE: CE) has announced a collaboration with Johns Hopkins University Department of Ophthalmology to study sustained drug delivery to the eye's suprachoroidal space. This approach aims to reduce the frequency of ocular injections for retinal disorders. Utilizing the VitalDose® Drug Delivery Platform, the bioinert implant promises over six months of continuous therapeutic delivery, enhancing patient compliance. The Celanese Development & Feasibility Lab will conduct parts of the research, supporting the development of long-acting drug delivery systems.

Celanese remains committed to improving healthcare solutions in ophthalmology and other fields.